FDA Approves Lipfendra, a New Oral Medication for Lowering LDL Cholesterol
The U.S. Food and Drug Administration (FDA) has recently approved Lipfendra, an oral medication that represents a significant breakthrough in the treatment of high cholesterol. This drug is the first in its class that can be taken in pill form, as previous options have primarily been administered through injections. Lipfendra, also known as enlicitide, functions by blocking the PCSK9 protein, which is known to elevate cholesterol levels and increase the risk of cardiovascular disease.
This new medication could be especially beneficial for the approximately 25% of the population dealing with hypercholesterolemia, a condition characterized by elevated levels of low-density lipoprotein (LDL) cholesterol, commonly referred to as "bad" cholesterol. The FDA's approval was based on the results of two late-stage clinical trials, which demonstrated that Lipfendra could lower LDL cholesterol levels by an average of nearly 60% in patients suffering from this condition.
Unlike traditional oral statins that inhibit an enzyme in the liver responsible for cholesterol production, Lipfendra acts as a PCSK9 inhibitor, offering a more powerful effect on reducing LDL levels. According to Merck, the drug's manufacturer, Lipfendra may serve as an effective add-on treatment for patients already taking statins, particularly since many individuals on these therapies do not meet recommended cholesterol management goals.
Merck's Executive Vice President, Brian Foard, highlighted the potential of Lipfendra, noting that approximately 70% of patients treated with existing therapies still fail to achieve guideline-recommended cholesterol levels. This new medication also targets individuals with genetic predispositions to high cholesterol, a group that often finds it challenging to manage their condition through lifestyle changes alone.
Importantly, the large clinical trials conducted for Lipfendra indicated that it does not carry the same allergy risks associated with injectable PCSK9 inhibitors from other manufacturers. RBC Capital Markets analyst Trung Huynh pointed out that despite the availability of injectable options for over a decade, a significant number of high-risk patients remain undertreated due to factors such as aversion to injections, prior authorization hurdles, and limited access to specialists in primary care settings.




